印度代购正品提示您，色瑞替尼(Ceritinib)是FDA加速审批用于治疗肺癌的靶向药，获批用于有间变性淋巴瘤激酶(ALK)-阳性转移对克唑替尼进展或不能耐受的非小细胞肺癌(NSCLC)患者的治疗。

 Ceritinib is a targeted drug approved for the treatment of non-small cell lung cancer (NSCLC) in patients with anaplastic lymphoma kinase (ALK) -positive metastases that have progressed or are intolerant to crizotinib.

印度代购正品提示您，色瑞替尼(Ceritinib)治疗ALK阳性晚期耐药NSCLC的Ⅰ期研究ASCEND-1结果对于纳入的246例NSCLC患者，研究显示，无论是否曾接受克唑替尼治疗，ALK阳性NSCLC患者均可从色瑞替尼中获益。

印度代购正品提示您，近期，针对ALK阳性晚期非小细胞肺癌耐药后治疗的ASCEND-2 Ⅱ期研究(发表在JCO)显示，色瑞替尼(Ceritinib)的全身和颅内反应良好，毒性可控。

印度代购正品提示您，承接ASCEND-1，ASCEND-2主要目标患者群体为克唑替尼治疗耐药合并脑转移的晚期NSCLC。克唑替尼是一种口服型小分子ATP竞争性的ALK抑制剂，可以抑制c-Met激酶，破坏c-Met的信号转导通路，进而抑制ALK融合基因，达到抑制肿瘤细胞生长的效果。而色瑞替尼是第二代ALK抑制剂，2014年4月被美国FDA批准上市，作为克唑替尼耐药后的治疗。

The main target patient group for ASCEND 1 and ASCEND 2 is crizotinib for the treatment of advanced NSCLC with drug resistance and BMS. Crizotinib is an oral small-molecule ATP-competitive ALK inhibitor, which can inhibit C-Met kinase, destroy c-MET signal transduction pathway, and then inhibit ALK fusion gene to achieve the effect of inhibiting tumor cell growth. Serotinib, a second-generation ALK inhibitor, was approved by THE US FDA in April 2014 as a treatment for crizotinib resistance.